Joindre l'IPC

04 91 22 33 33

 Prendre rendez-vous

04 91 22 30 30

Research is essential but of course the patient is our top priority

Research is essential but of course the patient is our top priority

Our goal, every day, is to turn cancer patients into cancer survivors.

Pr P. VIENS,
Director of IPC

We constantly apply discoveries from the laboratory to improve patients care

We constantly apply discoveries from the laboratory to improve patients care

We also bring what we learn from patients back to the lab to enhance our understanding of basic cancer biology.

Pr N. VEY,
notably Head of the ETOH

We have a bench-to-bedside approach

We have a bench-to-bedside approach

which allows us to move laboratory discoveries swiftly into the patient-care setting, while helping researchers refine therapies and techniques based on clinical observations.

Dr J.F. SAUNIÈRE,
Translational medicine Unit

The CRCM is one of the leading centers of biomedical research in France

The CRCM is one of the leading centers of biomedical research in France

Getting scientists and clinicians to work together on a daily basis to address critical issues in cancer biology.

Pr J.P. BORG,
Director of the CRCM
and Scientific Director of Institut Paoli-Calmettes

Les essais cliniques sont un paramètre essentiel

Les essais cliniques sont un paramètre essentiel

Ils nous permettre de mieux comprendre le cancer et nous aident à développer des traitements plus efficaces et moins toxiques.

Dr D. GENRE,
Responsable du Département de Recherche Clinique et d'innovation

Latest News

Tuesday 12 December 2017

La Fondation Groupe EDF soutient le « NANO-S »


More

Event

From Tuesday, Jan 30th 2018 at 01:00 PM
To Tuesday, Jan 30th 2018 at 02:00 PM
Organized by Pascale Zimmermann

Renaud Legouis: Autophagy and Development : Lessons from C. elegans


Read more

Highlighted publications

Cell, Cell Rep, Nat Commun, PNAS: our 5 latest publications

 

 

Eroded telomeres are rearranged in quiescent fission yeast cells through duplications of...


More

Keynote Lectures

On Wednesday, Feb 28th 2018 at 11:00 AM
Organized by Jean-Paul Borg

Jean-Pierre Sauvage: Machines moléculaires : de la biologie aux composés synthétiques


Read more

Questions to Jean-Paul Borg, Scientific Director of IPC

Introduction to research activities with Jean-Paul Borg, Scientific Director of Institut Paoli-Calmettes

What is distinctive about an institute like ours is the combination of research and care in one place.

The goal of the reorganization of our research, effective in 2012, is to bring even closer all players contributing to the advancement of our discipline: the discoverers of the targets of basic research, translational research experts that guide these discoveries to applications, oncologists and personnel that evaluate the efficacy and safety in clinical development of these new treatments and to make available the 80,000 samples of our biobank and the best technology and engineering. In practical terms this also means:

  • A new building that houses nearly one hundred researchers from CNRS, INSERM, the IPC and the new Aix-Marseille University.
  • A new team dedicated to translational research and evaluation of therapeutic drug candidates.
  • New tools such as the platform for preclinical evaluation TrGET ® or the unit dedicated to early clinical trials, ETOH.
  • New vocations: project manager, research organizer, research nurse...
  • Exploring new avenues of research, such as mechanisms of DNA repair or the relationship between cellular stress and cancer.
  • Finally, a new project-based organization that promotes the emergence of innovative approaches in areas of historical expertise of the Institute: hematologic malignancies, breast, digestive and urogenital cancers.

If we want to advance our knowledge in oncology it is imperative that research be closely involved in the care of patients.

This is because research in the IPC is first and foremost determined by the needs of the oncologist and his patient but also because the manner in which the patient responds to treatment is full of information for the researcher, whether he is oriented to fundamental or more applied studies. In this way, when a patient is resistant to treatment, the researcher quickly explores the biological peculiarities of the tumor to identify a potential biomarker associated with this resistance. Once validated, this biomarker will be used by the oncologist to stratify patients and use this treatment only for patients who may benefit from it.

Of course, the strength of the IPC is its scientific and medical excellence and advanced technology but also the constant questioning and the collaborative culture that make possible the continuous back and forth interaction between biology and the clinic.

A new building houses nearly one hundred researchers